| scholarly article | Q13442814 |
| P50 | author | Francesco Luigi Gervasio | Q54665519 |
| P2093 | author name string | David T Clarke | |
| Laura C Zanetti-Domingues | |||
| Marisa L Martin-Fernandez | |||
| Selene K Roberts | |||
| P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
| EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization | Q24296900 | ||
| Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface | Q24301761 | ||
| Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha | Q24307630 | ||
| Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains | Q24307661 | ||
| Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment | Q24309071 | ||
| Conformational coupling across the plasma membrane in activation of the EGF receptor | Q24313122 | ||
| Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization | Q24321210 | ||
| The Protein Data Bank | Q24515306 | ||
| The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand | Q24536067 | ||
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| Energy transfer: a spectroscopic ruler | Q24618609 | ||
| ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation | Q24621754 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects. Studies with cholesterol enantiomers | Q24650803 | ||
| A conserved protonation-dependent switch controls drug binding in the Abl kinase | Q24657421 | ||
| Non-small cell lung cancer: current treatment and future advances | Q26740333 | ||
| Molecular dynamics simulations: advances and applications | Q26775869 | ||
| A practical guide to small angle X-ray scattering (SAXS) of flexible and intrinsically disordered proteins | Q26796304 | ||
| Markov state models of biomolecular conformational dynamics | Q26827934 | ||
| Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer | Q27305848 | ||
| A primer to single-particle cryo-electron microscopy | Q27322872 | ||
| Conformational Changes in the Epidermal Growth Factor Receptor: Role of the Transmembrane Domain Investigated by Coarse-Grained MetaDynamics Free Energy Calculations | Q27336007 | ||
| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) | Q27639449 | ||
| Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor | Q27639528 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity | Q27644014 | ||
| The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain | Q27646344 | ||
| Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 | Q27646596 | ||
| 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases | Q27649889 | ||
| 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors | Q27651329 | ||
| ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor | Q27657234 | ||
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M | Q27658766 | ||
| Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor | Q27664452 | ||
| Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain | Q27674725 | ||
| Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor | Q27677383 | ||
| Sequence Determinants of a Specific Inactive Protein Kinase Conformation | Q27678722 | ||
| Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains | Q27678732 | ||
| Mechanism for activation of mutated epidermal growth factor receptors in lung cancer | Q27679902 | ||
| A single ligand is sufficient to activate EGFR dimers | Q27681167 | ||
| Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition | Q27683650 | ||
| Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors | Q27737008 | ||
| N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor | Q39946177 | ||
| Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane. | Q39977877 | ||
| Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding. | Q40155127 | ||
| Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor | Q40353804 | ||
| Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis | Q40402524 | ||
| Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro | Q40693948 | ||
| Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain | Q40782870 | ||
| Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. | Q40817131 | ||
| Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region. | Q40820169 | ||
| How Hsp90 and Cdc37 Lubricate Kinase Molecular Switches | Q41596905 | ||
| Occupy EGFR. | Q41976220 | ||
| Interactions of the EGFR juxtamembrane domain with PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics simulations | Q41984481 | ||
| Regulation of receptor tyrosine kinase ligand processing | Q41994915 | ||
| Ligand-induced structural transitions in ErbB receptor extracellular domains | Q42032357 | ||
| Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer | Q43061055 | ||
| EGFR: Tale of the C‐terminal tail | Q43080915 | ||
| Fluorescence Lifetime Imaging Microscopy for Quantitative Biological Imaging | Q44732189 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Incidence and mortality of lung cancer: global trends and association with socioeconomic status | Q45489340 | ||
| A structural model for the membrane-bound form of the juxtamembrane domain of the epidermal growth factor receptor | Q46445840 | ||
| Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. | Q46462162 | ||
| N-glycan of ErbB family plays a crucial role in dimer formation and tumor promotion. | Q46883768 | ||
| Pockets as structural descriptors of EGFR kinase conformations | Q47162698 | ||
| The Interplay between Structural Stability and Plasticity Determines Mutation Profiles and Chaperone Dependence in Protein Kinases. | Q47269892 | ||
| EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics | Q47680913 | ||
| Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding. | Q48117891 | ||
| Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling | Q49805726 | ||
| The biology and management of non-small cell lung cancer | Q49826396 | ||
| Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors | Q36200403 | ||
| HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation | Q36322762 | ||
| Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system | Q36423352 | ||
| The epidermal growth factor receptor pathway: a model for targeted therapy | Q36603677 | ||
| An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase | Q36785393 | ||
| Transitions to catalytically inactive conformations in EGFR kinase | Q36820157 | ||
| Architecture and membrane interactions of the EGF receptor | Q36923502 | ||
| Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase | Q36967631 | ||
| Molecular basis for multimerization in the activation of the epidermal growth factor receptor | Q36993693 | ||
| Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors | Q37057914 | ||
| Origins of growth factors: NGF and EGF. | Q37142765 | ||
| Structure-based view of epidermal growth factor receptor regulation | Q37197992 | ||
| Using plasma membrane nanoclusters to build better signaling circuits | Q37213906 | ||
| The epidermal growth factor receptor ligands at a glance | Q37324458 | ||
| Characterization of Glycosylation Sites of the Epidermal Growth Factor Receptor | Q37396323 | ||
| The genesis of tyrosine phosphorylation | Q37718124 | ||
| A systematic approach to protein glycosylation analysis: a path through the maze | Q37790268 | ||
| Feedback regulation of EGFR signalling: decision making by early and delayed loops. | Q37831109 | ||
| The EGFR family: not so prototypical receptor tyrosine kinases | Q38201344 | ||
| Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms | Q38286343 | ||
| Synthesis of epidermal growth factor receptor in human A431 cells. Glycosylation-dependent acquisition of ligand binding activity occurs post-translationally in the endoplasmic reticulum. | Q38350230 | ||
| Analysis of the glycosylation patterns of the extracellular domain of the epidermal growth factor receptor expressed in Chinese hamster ovary fibroblasts | Q38363065 | ||
| Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes | Q38623447 | ||
| Advances in free-energy-based simulations of protein folding and ligand binding. | Q38698407 | ||
| EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR. | Q38731480 | ||
| Role of N-glycosylation in EGFR ectodomain ligand binding | Q38795554 | ||
| Changes in the free-energy landscape of p38α MAP kinase through its canonical activation and binding events as studied by enhanced molecular dynamics simulations | Q38818757 | ||
| Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells | Q38866417 | ||
| Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line | Q39114552 | ||
| Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". | Q39346046 | ||
| Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. | Q39405800 | ||
| Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells | Q39468370 | ||
| Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling | Q39616171 | ||
| Spatial control of EGF receptor activation by reversible dimerization on living cells | Q39731307 | ||
| Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib | Q39897755 | ||
| Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fluorescence lifetime imaging microscopy | Q50847753 | ||
| Ins and Outs of Kinase DFG Motifs | Q50888279 | ||
| Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase | Q50959142 | ||
| Free-energy landscape for beta hairpin folding from combined parallel tempering and metadynamics | Q51931397 | ||
| Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations | Q51934736 | ||
| Therapeutic uses of HSP90 inhibitors in Non-Small Cell Lung Carcinoma (NSCLC). | Q52665088 | ||
| New developments in force fields for biomolecular simulations. | Q52687239 | ||
| The effect of a widespread cancer-causing mutation on the inactive to active dynamics of the B-Raf kinase | Q54278360 | ||
| Conformational regulation of the EGFR kinase core by the juxtamembrane and C‐terminal tail: A molecular dynamics study | Q54644212 | ||
| EGFR signaling patterns are regulated by its different ligands. | Q55070997 | ||
| Developing a molecular dynamics force field for both folded and disordered protein states. | Q55310411 | ||
| Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas | Q55480632 | ||
| Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck | Q56770481 | ||
| New advances in immunotherapy for non-small cell lung cancer | Q56890070 | ||
| Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design | Q57794187 | ||
| The Different Flexibility of c-Src and c-Abl Kinases Regulates the Accessibility of a Druggable Inactive Conformation | Q58465773 | ||
| Protein Conformational Transitions: The Closure Mechanism of a Kinase Explored by Atomistic Simulations | Q58465787 | ||
| The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers | Q58600328 | ||
| Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer | Q58726253 | ||
| Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma | Q59566032 | ||
| Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | Q59800637 | ||
| Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket | Q59828149 | ||
| Characterization of the N-oligosaccharides attached to the atypical Asn-X-Cys sequence of recombinant human epidermal growth factor receptor | Q73580767 | ||
| The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization. Possible role of a specific sugar chain in controllable receptor activation | Q73763333 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors | Q80103312 | ||
| Targeting tyrosine kinases in cancer: the second wave | Q83854401 | ||
| On the nature of low- and high-affinity EGF receptors on living cells | Q34595942 | ||
| Oligomerization and nanocluster organization render specificity | Q34681546 | ||
| Endocytosis and intracellular trafficking of ErbBs | Q34827744 | ||
| Regulation of human EGF receptor by lipids | Q35021986 | ||
| Solid-state NMR and membrane proteins | Q35214037 | ||
| Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. | Q35219426 | ||
| N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes | Q35378448 | ||
| ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding | Q35534115 | ||
| Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding | Q35568374 | ||
| The Membrane-proximal Intracellular Domain of the Epidermal Growth Factor Receptor Underlies Negative Cooperativity in Ligand Binding | Q35639911 | ||
| A structural perspective on the regulation of the epidermal growth factor receptor | Q35674768 | ||
| Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition | Q35699603 | ||
| The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function | Q35729931 | ||
| Ligand regulation of a constitutively dimeric EGF receptor | Q35733874 | ||
| Activation pathway of Src kinase reveals intermediate states as targets for drug design | Q35738216 | ||
| The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study | Q35752926 | ||
| Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations | Q35820920 | ||
| Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy | Q35850949 | ||
| Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis | Q35878699 | ||
| Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor | Q35917462 | ||
| The ErbB receptors and their ligands in cancer: an overview. | Q36108987 | ||
| Demonstrating an Order-of-Magnitude Sampling Enhancement in Molecular Dynamics Simulations of Complex Protein Systems | Q87271292 | ||
| Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC) | Q89170235 | ||
| Towards simple kinetic models of functional dynamics for a kinase subfamily | Q89486452 | ||
| Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers | Q89998161 | ||
| Overcoming resistance in non-small-cell lung cancer: A practical lesson for the medicinal chemist | Q90910643 | ||
| Understanding the biology of HER3 receptor as a therapeutic target in human cancer | Q90952252 | ||
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC | Q91517934 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| All-atom empirical potential for molecular modeling and dynamics studies of proteins | Q27860468 | ||
| Signal transduction by receptors with tyrosine kinase activity | Q27860624 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| The conformational plasticity of protein kinases | Q27860946 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Dynamics of folded proteins | Q28287584 | ||
| Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor | Q28541111 | ||
| Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics | Q28551159 | ||
| Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation | Q28590384 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 | ||
| Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells | Q29616544 | ||
| Precise nanometer localization analysis for individual fluorescent probes | Q29617300 | ||
| HSP90 and the chaperoning of cancer | Q29617504 | ||
| Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop | Q30009548 | ||
| A tale of the epidermal growth factor receptor: The quest for structural resolution on cells. | Q30380491 | ||
| Revealing Higher Order Protein Structure Using Mass Spectrometry. | Q30386904 | ||
| EGFR oligomerization organizes kinase-active dimers into competent signalling platforms | Q30827493 | ||
| Computation of conformational coupling in allosteric proteins | Q30872872 | ||
| Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases | Q31036423 | ||
| Structure of caveolae | Q33224886 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Co-conserved features associated with cis regulation of ErbB tyrosine kinases | Q33778237 | ||
| Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells | Q33944231 | ||
| Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor | Q33981031 | ||
| Conformational Transition Pathways of Epidermal Growth Factor Receptor Kinase Domain from Multiple Molecular Dynamics Simulations and Bayesian Clustering | Q34045014 | ||
| EGF receptor ligands | Q34185050 | ||
| Autophosphorylation sites on the epidermal growth factor receptor. | Q34245370 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Higher-Order Assemblies in a New Paradigm of Signal Transduction | Q34338941 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P577 | publication date | 2019-04-05 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer | |
| P478 | volume | 8 |
| Q92068202 | Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles | cites work | P2860 |
Search more.